Literature DB >> 6245354

Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission.

Y I Kim, M M Goldner, D B Sanders.   

Abstract

The effects of 4-aminopyridine (4-AP) on neuromuscular transmission were studied in vitro in the rat flexor digitorum longus muscles. 4-AP produced dose-dependent increases in endplate potential (EPP) amplitude, in rise time to peak, and in the average number of acetylcholine quanta released by presynaptic nerve impulses. The neuromuscular blocking effects of d-tubocurarine or low Ca2+/high Mg2+ concentrations could be completely reversed by 4-AP, and EPPs developed into muscle action potentials (APs). The drug had minimal effects on the amplitude or frequency of spontaneous miniature endplate potentials, but increased the duration of indirectly elicited muscle APs. The action of 4-AP required the presence of extracellular Ca2+; thus, its effect may be to promote Ca2+ entry into the motor nerve terminal, and thereby increase the neurally evoked transmitter release. 4-AP is effective in overcoming both presynaptic and postsynaptic blockade of neuromuscular transmission, suggesting a potential role for this drug in the treatment of neuromuscular diseases.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245354     DOI: 10.1002/mus.880030202

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Multiple potassium conductances at the mammalian motor nerve terminal.

Authors:  D A Saint; D M Quastel; Y Y Guan
Journal:  Pflugers Arch       Date:  1987-11       Impact factor: 3.657

2.  Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine.

Authors:  D B Sanders; Y I Kim; J F Howard; C A Goetsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

3.  The effects of 4-aminopyridine and tetrodotoxin on the release of acetylcholine from rat striatal slices.

Authors:  V Dolezal; S Tucek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000

Review 4.  Dalfampridine extended release: in multiple sclerosis.

Authors:  Claudine M Chwieduk; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

5.  Dalfampridine effects on cognition, fatigue, and dexterity.

Authors:  Melanie Korsen; Rhina Kunz; Ulf Schminke; Uwe Runge; Thomas Kohlmann; Alexander Dressel
Journal:  Brain Behav       Date:  2016-11-11       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.